image description

Tag: Jill Buyon

Family Planning and Lupus

The LRA is committed to supporting research and resources to better address the complexities of pregnancy in lupus.  This video webinar addresses preconception counseling, suitability for pregnancy, impact of lupus medication, lupus flares, support, and much more. Gain knowledge and perspective as our distinguished panel of physicians, Dr. Jill P. Buyon and Dr. Shilpi Mehta-Lee, […] Read More

LRA-Funded Study Finds Lazy Enzyme that Triggers Autoimmunity

April 14, 2021 Dr. Boris Reizis and his team, working with a group of clinical rheumatologists led by Dr. Jill Buyon, have made a connection between an enzyme that prevents people’s immune systems from reacting to their own DNA and lupus activity. In a paper just published in the Journal of Experimental Medicine they report […] Read More

Good News on Lupus Nephritis Discoveries from ACR Convergence 2020

November 19, 2020 The LRA is proud to share the extraordinary work presented at ACR Convergence 2020 by research members of the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE).  AMP is a public-private partnership between the National Institutes of Health (NIH), eight biopharmaceutical companies, the LRA and several […] Read More

NIH Work Co-Supported by LRA May Simplify Lupus Nephritis Monitoring

June 20, 2019 As reported by the National Institutes of Health (NIH), research published by the NIH Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) “provides new insights into tissue damage for these autoimmune conditions.” AMP RA/SLE is a public-private partnership between the NIH, the pharmaceutical industry and non-profit organizations, including the Lupus […] Read More

Advancing Research Exponentially

August 14, 2018 Advancing Research Exponentially An Update on AMP by Jill Buyon, MD Lupus nephritis (LN), one of the dreaded complications of lupus, causes patients to suffer, sometimes for decades, with no new treatment in sight. But now is the time to leverage technology for major advances, which is exactly what the Accelerating Medicines […] Read More